EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aquestive Therapeutics's Enterprise Value is $375.62 Mil.
Aquestive Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.38 Mil. Therefore, Aquestive Therapeutics's EV-to-FCF for today is -50.93.
The historical rank and industry rank for Aquestive Therapeutics's EV-to-FCF or its related term are showing as below:
AQST'
s EV-to-FCF Range Over the Past 10 Years
Min: -56.83 Med: -3.55 Max: 60.54
Current: -50.93
During the past 8 years, the highest EV-to-FCF of Aquestive Therapeutics was 60.54. The lowest was -56.83. And the median was -3.55.
AQST's EV-to-FCF is ranked worse than 100% of 511
companies
in the Drug Manufacturers industry
Industry Median: 22.05
vs AQST: -50.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aquestive Therapeutics's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's EV-to-FCF falls into.
Aquestive Therapeutics's current Enterprise Value is $375.62 Mil.
Aquestive Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aquestive Therapeutics's PE Ratio for today is calculated as:
Aquestive Therapeutics's share price for today is $4.07.
Aquestive Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.154.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aquestive Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Aquestive Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Aquestive Therapeutics (Aquestive Therapeutics) Business Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your 